Cambridge Isotope Laboratories, Inc. (CIL) is the world’s leading producer of stable isotopes and stable isotope-labeled compounds. With over 600 employees and laboratories in four countries, CIL specializes in the process of labeling biochemical and organic compounds with highly enriched, stable (nonradioactive) isotopes of carbon, hydrogen, nitrogen and oxygen. Our chemists substitute common atoms (e.g., 1H, 12C, 14N, 16O) with rare, highly valued isotopes (e.g., 2H or D, 13C, 15N, 18O) so that the final product can be readily measured or traced using mass spectrometry (MS) or nuclear magnetic resonance (NMR). CIL’s products are utilized in laboratories, medical, government and academic research centers and health care facilities worldwide.

We are proud that CIL products have contributed to medical advancements in cancer research, new-drug development, environmental analysis, and medical diagnostic research. In the past decade, as the fields of proteomics and metabolomics have developed as leading techniques for determining biomarkers for disease presence, progression and the monitoring of therapeutic response, CIL has worked closely with industry leaders and researchers to provide the stable isotope-labeled tools needed for improved quantitation and qualification of complex biological systems.

After decades of research, stable isotopes have found their place in an ever expanding commercial scale applications in pharmaceuticals, semiconductors, flat panel displays as well as other high technology fields specifically with deuterium oxide (D2O) and deuterium gases. Pharmaceutical companies have begun to investigate deuteration of molecules that may provide advantages over their existing nondeuterated counterparts. In addition, increasing research into the potential medical advantages of new deuterated drugs is also occurring. In high technology, deuterated organic molecules and deuterium gas are commonly used in the manufacturing of microelectronics and OLEDs, which contribute to the increased lifetime of the devices.

CIL's vision began when it was founded in 1981 by Dr. Joel Bradley, an organic chemist from MIT. Drawing on a commitment to high-quality products, superior customer service, innovative new products and breadth of product lines, CIL quickly emerged as a leader in its field. CIL now produces more than 15,000 products and has ISO 13485, ISO/IEC 17025 and ISO 17034 quality systems, as well as cGMP production capabilities. CIL was acquired by the the Otsuka Group in 1998 and over the past several decades has increased its global footprint and now has over 500 employees in its facilities located in five countries. CIL is comprised of five companies: Cambridge Isotope Laboratories, Inc. (CIL) and CIL Isotope Separations, LLC (CIS) in the US; CIL Canada in Montreal, Canada; Euriso-Top in Saclay, France; Cambridge Isotope Laboratories - China in Shanghai, China and ABX GmbH in Dresden, Germany.   
 
CIL’s state-of-the-art production facilities are located at the company’s headquarters in Tewksbury, Massachusetts, and the company’s primary production laboratories are located in Andover, Massachusetts. Our isotope-separation facility located in Xenia, Ohio, houses the world’s largest 13C and one of the world’s largest 18O isotope-separation facilities. This facility also houses the world’s only commercial D2O enrichment columns.

CIL is committed to quality and service and our experts support all of our customers to aid in pivotal research that is being conducted in laboratories worldwide. Our partnerships not only help to support our global reach but allow us to bring forward innovative products in our pursuit of enriching scientific discovery.